sb 202190 has been researched along with Endometrial Neoplasms in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
Excerpt | Relevance | Reference |
---|---|---|
"Endometrial carcinoma is the most common neoplasm of the female genital tract, accounting for nearly one half of all gynecologic cancers in the Western world." | 1.35 | Gonadotropin-releasing hormone (GnRH)-I and GnRH-II induce cell growth inhibition in human endometrial cancer cells: involvement of integrin beta3 and focal adhesion kinase. ( Choi, KC; Leung, PC; MacCalman, CD; Park, DW, 2009) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Park, DW | 1 |
Choi, KC | 1 |
MacCalman, CD | 1 |
Leung, PC | 1 |
1 other study available for sb 202190 and Endometrial Neoplasms
Article | Year |
---|---|
Gonadotropin-releasing hormone (GnRH)-I and GnRH-II induce cell growth inhibition in human endometrial cancer cells: involvement of integrin beta3 and focal adhesion kinase.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Endometri | 2009 |